Blockchain Registration Transaction Record

OS Therapies to Present at Moody Capital Conference, Advancing Cancer Treatment for Pets

OS Animal Health, a subsidiary of OS Therapies (NYSE: OSTX), presents at Moody Capital Conference, advancing OST-HER2 for canine osteosarcoma. Learn about this innovative immunotherapy.

This news matters for pet owners and the veterinary community because it signals progress in the fight against canine cancer. OS Therapies' OST-HER2 could become a groundbreaking treatment for osteosarcoma, a devastating disease in dogs. The company's participation in the Moody Capital conference highlights its growth potential and may attract investment to accelerate development. If successful, OST-HER2 could not only improve and extend the lives of pets but also pave the way for similar immunotherapies in other companion animals and potentially contribute to human cancer research, as HER2-positive cancers are prevalent in both species.